Hair Loss While Taking a GLP-1: What Women Should Know

What hair loss from GLP-1 medications can look like in women

One cause of shedding after a big change in the body is telogen effluvium. Cleveland Clinic describes it as a temporary type of hair loss caused by a stressor or a change to the body. Harvard Health explains that more hairs get pushed into the resting phase of the hair cycle, and that you may not notice the extra shedding until two to four months after the event. Numbers wise, Harvard puts the average at about 100 hairs lost a day, which can rise to around 300 with telogen effluvium.

Cleveland Clinic lists the usual signs as more hair in your brush, in the shower drain or on your pillow, and thinning on the scalp, most often on the top of the head. A part that looks wider or a ponytail that feels thinner can also be a sign of female pattern hair loss, according to the American Academy of Dermatology (AAD). That can mean that these changes don't point to a diagnosis by themselves, and only a clinician can tell you what you have.

With telogen effluvium, Cleveland Clinic says the scalp should look healthy, without a rash, itching, burning, pain or flaking. Those symptoms, or round bald patches, which the AAD links to alopecia areata, are worthmentioning to a dermatologist rather than 'seeing how it goes'.

Hormonal change can overlap with all of this. Harvard Health lists abrupt hormonal changes, including those linked to childbirth and menopause, among the triggers for telogen effluvium, so women in perimenopause or after menopause may find it harder to tell what is driving their shedding.

How common is hair loss from GLP-1 medications?

The official labels give the clearest numbers, and they apply to the named trials and doses, not automatically to every brand that shares an ingredient.

In Zepbound’s weight-loss trials, hair loss was reported by 5% of people on 5 mg, 4% on 10 mg, and 5% on 15 mg, compared with 1% on placebo. Among women, the rate was higher: 7.1%, versus 0.5% in men. The prescribing information links those reports to weight reduction.

Women reported it more often than men: 7.1% of women versus 0.5% of men on tirzepatide, and 1.3% of women versus 0% of men on placebo.

No one on tirzepatide stopped because of hair loss, and one person on placebo did.

In the US Wegovy prescribing information, pooled trials of semaglutide 2.4 mg in adults with obesity or overweight reported hair loss in 3% of people on Wegovy versus 1% on placebo (2,116 and 1,261 people). In the label's sex breakdown, 4% of women and 0.9% of men on Wegovy reported it, versus 2% of women and 0% of men on placebo.

Both labels describe the hair loss reports as associated with weight reduction. That is an association in the trial data, and it doesn't show weight loss is the only cause or that the medicine plays no part. The figures also come from separate trials in different populations, so they can't rank one medicine against another, and they don't cover Mounjaro or Ozempic, which have their own labels.

Hair loss from weight loss: why rapid change may lead to shedding

Hair cycles through a growing phase, a short transition, and a resting phase before a strand sheds. Harvard Health lists surgery, extreme weight loss, an extreme change in diet, and some medications among the events that can push more follicles into the resting phase together. The shedding follows months later, which is why a hard month on the scale and a hard month in the brush don't line up.

On a GLP-1 medicine, weight loss, eating much less, and the medicine itself can all be happening at once, and the sources used here can't separate them. The EU Wegovy product information says hair loss was reported more often in people who lost 20% or more of their body weight, and that the events were mainly mild, with most people recovering while they continued the medicine in tablet form. That describes what happened in the trials and can't predict what will happen for you.

When GLP-1 shedding can start and how long it can last

General guidance on telogen effluvium gives ranges, not a reliable schedule. Cleveland Clinic says shedding usually begins two to three months after the stressor, usually lasts three to six months, and that hair typically grows back in three to six months. Harvard Health says it rarely lasts longer than six months, although some cases do.

Those figures come from general telogen effluvium guidance and not from studies of women taking GLP-1 medicines, so treat them as a rough guide. Some cases last longer, and Cleveland Clinic describes chronic telogen effluvium as lasting more than six months.

Can you stop hair loss from a GLP-1? Steps and questions worth raising

The sources reviewed for this article don't show that any specific supplement, diet or protein target prevents hair loss on a GLP-1 medicine. What they do support is a set of questions worth taking to a clinician.

Nutrition and blood tests

A joint advisory from four US medical and nutrition societies, including the Obesity Medicine Association and the American Society for Nutrition, discusses protein and other nutrition during GLP-1 therapy. Its protein ranges are individualized nutrition guidance for people losing weight, and aren't a way to prevent hair loss.

In a claims-data study of 461,382 adults newly prescribed a GLP-1 medicine, most of them with type 2 diabetes, 12.7% had a coded nutritional deficiency or related complication within six months and 22.4% within 12 months. Vitamin D deficiency was the most common single diagnosis (7.5% and 13.6%). Its main analysis had no comparison group and counted diagnoses recorded in claims, so it can't say how much of this is caused by the medicine, and it can't tell you which tests you need. Whether blood tests make sense for you, and which ones, is a decision for a clinician who knows your history, diet and symptoms.

Hair care habits

Thinning hair is fragile and easily damaged, according to the AAD. Its tips include brushing or combing gently and only enough to style your hair, not wearing hair tightly pulled back in a bun or ponytail, and stopping at-home coloring, perming, chemical straightening and relaxing. These tips are about protecting fragile hair, and they aren't presented as a way to shorten shedding.

Biotin and lab tests

The FDA warns that biotin can significantly interfere with certain lab tests and cause incorrect results that may go undetected, and it has received adverse event reports of biotin causing falsely low troponin results. If you take a biotin supplement, tell whoever orders your blood tests.

Questions to bring to an appointment

• When did the shedding start in relation to your dose changes and weight loss?

• Is there a history of thinning in your family, or did you notice thinning before the medication?

• Which medications and supplements are you taking, biotin included?

• Does it look like heavy shedding, or like slower thinning with a widening part?

• Would blood tests help in your case, and which ones?

• Your prescriber or a dermatologist can work through these with you.

Options a dermatologist may discuss

Telogen effluvium and female pattern hair loss are different problems that can overlap. Cleveland Clinic describes telogen effluvium as heavy shedding and rapid loss, and female pattern hair loss as slow thinning. The AAD says female pattern hair loss often shows up as a widening part. The right option depends on which one a dermatologist finds on examination.

Topical minoxidil in 2% and 5% strengths is FDA-approved for female pattern hair loss, according to the AAD. Oral minoxidil is used off-label for hair loss, and studies of low-dose oral minoxidil in women, such as Ramos et al. and Nascimento e Silva et al., were done in women with pattern hair loss, not GLP-1 shedding. The AAD notes that minoxidil can make hair grow in places other than the scalp, such as the cheeks and forehead. For oral minoxidil, a prescriber has to weigh your overall health, including blood pressure and heart history, before recommending it. No study reviewed for this article tests minoxidil for hair loss on a GLP-1 medicine.

When to see a dermatologist and whether to change your GLP-1 dose

It can feel strange to watch the number on the scale finally move while something you didn't bargain for shows up in the mirror.

A 2026 target trial emulation in the BMJ, an observational study using Penn Medicine health records on adults with type 2 diabetes, linked GLP-1 use to a higher risk of alopecia than SGLT-2 inhibitor use. The authors described the absolute risk as low: 6.91 cases per 1,000 person-years on GLP-1 drugs versus 5.04 on SGLT-2 inhibitors.

Reports to the FDA's adverse event reporting system have also raised alopecia as a signal for semaglutide and tirzepatide, in an analysis by Godfrey et al. discussed in a commentary by Buontempo and Santos. Reporting signals can't show how often hair loss happens or prove that a medicine caused it.

You don't need to wait for a set number of months to ask for help. Cleveland Clinic advises contacting a healthcare provider as soon as you notice hair loss, especially if it is causing you stress, and the American Academy of Dermatologyadvises talking with your doctor if you suspect a medication is causing it. Patchy or scarring changes, scalp symptoms, or a widening part are all reasons to go sooner.

Any change to dose or schedule belongs in a conversation with the prescriber managing your GLP-1, weighed against the full picture of your health, not decided over a few bad hair days on your own. No source reviewed here shows that a slower dose increase prevents shedding.

FAQ

Will my hair grow back after stopping Ozempic?

Cleveland Clinic says hair typically grows back in three to six months with telogen effluvium, but that is general guidance and not from GLP-1 studies, and recovery isn't guaranteed. The sources behind this article don't show what happens to hair after stopping Ozempic or any other GLP-1 medicine. Whether to stop is a decision for your prescriber, and shedding that worries you is worth having assessed either way.

Is there a way to stop hair loss from Ozempic overnight?

No. Nothing in the sources behind this article explains how to stop hair loss from Ozempic overnight, because no quick fix, supplement or otherwise, has been shown. Shedding from telogen effluvium is usually noticed some months after the trigger, and several other causes of hair loss exist, so a clinician's assessment is the useful first step.

Is hair loss from Zepbound more common than with other GLP-1 drugs?

The trials can't answer that. Each label reports its own population, doses and placebo group, so Zepbound's 4% to 5% and Wegovy's 3% shouldn't be ranked against each other. Both labels describe the reports as associated with weight reduction.

Do any vitamins help with GLP-1 hair loss?

The sources reviewed here don't point to a vitamin that prevents hair loss on a GLP-1 medicine. Nutritional deficiencies were recorded in a share of GLP-1 users in the Butsch study, but whether you need testing, and for what, is a clinician's call based on your own history.

How can I tell if this is telogen effluvium or female pattern hair loss?

Cleveland Clinic describes telogen effluvium as heavy shedding and rapid loss, and female pattern hair loss as slow thinning, and the AAD says female pattern hair loss often shows up as a widening part. They can overlap and look alike, so don't try to diagnose yourself. A dermatologist can examine your scalp and tell you which one you have, or whether it is something else.

If my hair is falling out, should I stop my GLP-1 injections?

Don't stop or change your dose on your own. Talk with the prescriber managing your GLP-1, who can weigh your hair concern against the reason the medicine was prescribed. Shedding that is severe, patchy, painful or worrying you deserves assessment sooner rather than later.

Sources

All pages accessed October 13, 2026.

• Cleveland Clinic. Telogen Effluvium. Updated December 1, 2022. Sections on symptoms, acute and chronic telogen effluvium, duration and regrowth.

• Harvard Health Publishing. Telogen effluvium. Reviewed by Howard E. LeWine, MD. October 7, 2024.

• American Academy of Dermatology. Thinning hair and hair loss: Could it be female pattern hair loss? Last updated December 13, 2022. Sections on signs and minoxidil.

• American Academy of Dermatology. Do you have hair loss or hair shedding? No date shown.

• American Academy of Dermatology. Hair loss: Tips for managing. No date shown. Tips 4, 7 and 9.

• Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. Revised August 2026. Section 6.1 (Table 1; Hair Loss).

• Novo Nordisk. Wegovy (semaglutide) prescribing information. Revised June 2026. Section 6.1 (Table 3; Hair Loss).

• European Medicines Agency. Wegovy EPAR product information. Section 4.8 (Hair loss).

• Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars. 2025. doi:10.1016/j.obpill.2025.100181. Section on preservation of muscle and bone mass.

• Butsch WS, Sulo S, Chang AT, et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study. Obesity Pillars. 2025;15:100186. PMID 40584822.

• US Food and Drug Administration. Biotin Interference with Troponin Lab Tests. Content current as of June 21, 2022.

• Ramos PM, Sinclair RD, Kasprzak M, Miot HA. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: a randomized clinical trial. J Am Acad Dermatol. 2020;82(1):252–253. PMID 31473295.

• Nascimento e Silva M, Ramos PM, Silva MR, et al. Randomized clinical trial of low-dose oral minoxidil for the treatment of female pattern hair loss: 0.25 mg versus 1 mg. J Am Acad Dermatol. 2022;87(2):396–399. PMID 35077777.

• Tang H, Zhang B, Lu Y, et al. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ. 2026;394:e100077. doi:10.1136/bmj-2026-100077.

• Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol. 2025;39(2):e153–e154. PMID 38925559.

• Buontempo MG, Santos BT. Exploring the hair loss risk in glucagon-like peptide-1 agonists: emerging concerns and clinical implications. J Eur Acad Dermatol Venereol. 2025;39(2):263–264. PMID 39854119.

This article is for education only and is not medical advice. Talk with your healthcare provider about your own hair and scalp health.